GSK Receives US FDA Fast Track Designation for Bepirovirsen in Chronic Hepatitis B

London, UK 12 February 2024 -- GSK plc (LSE/NYSE: GSK) announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials